Evidence map›Paper›PMID 38332909›Full record

ArticleFrontiers in immunology2023

Serum S100A8/A9 and MMP-9 levels are elevated in systemic lupus erythematosus patients with cognitive impairment.

Carolina Muñoz-Grajales, Michelle L Barraclough, Juan P Diaz-Martinez, Jiandong Su, Kathleen Bingham, Mahta Kakvan, Roberta Pozzi Kretzmann, Maria Carmela Tartaglia, Lesley Ruttan, May Y Choi and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Towards precision medicine for systemic lupus erythematosus and neuropsychiatric manifestations.Expert review of precision medicine and drug development · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Carolina Muñoz-GrajalesSchroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada.
Michelle L BarracloughSchroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada.
Juan P Diaz-MartinezSchroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada.
Jiandong SuSchroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada.
Kathleen BinghamCentre for Mental Health, University Health Network, Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
Mahta KakvanSchroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada.
Roberta Pozzi KretzmannSchroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada.
Maria Carmela TartagliaDepartment of Medicine, Division of Neurology, University of Toronto Krembil Neurosciences Centre, Toronto, ON, Canada.
Lesley RuttanDepartment of Psychology, University Health Network-Toronto Rehabilitation Institute, Toronto, ON, Canada.
May Y ChoiCumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Simone AppenzellerSchool of Medical Science, Department of Orthopedics, Rheumatology and Traumatology, University of Campinas, São Paulo, Brazil.
Sherief MarzoukCentre for Mental Health, University Health Network, Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
Dennisse BonillaSchroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada.
Patricia KatzDivision of Rheumatology, Department of Medicine, and Institute for Health Policy Studies, University of California, San Francisco, Novato, CA, United States.
Dorcas BeatonInstitute for Work and Health, University of Toronto, Toronto, ON, Canada.
Robin GreenDepartment of Psychology, University Health Network-Toronto Rehabilitation Institute, Toronto, ON, Canada.
Dafna D GladmanSchroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada.
Joan WitherSchroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada.
Zahi ToumaSchroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Cognitive impairment (CI) is one of the most common manifestations of Neuropsychiatric Systemic Lupus Erythematosus (NPSLE). Despite its frequency, we have a limited understanding of the underlying immune mechanisms, resulting in a lack of pathways to target. This study aims to bridge this gap by investigating differences in serum analyte levels in SLE patients based on their cognitive performance, independently from the attribution to SLE, and exploring the potential for various serum analytes to differentiate between SLE patients with and without CI. Methods: Two hundred ninety individuals aged 18-65 years who met the 2019-EULAR/ACR classification criteria for SLE were included. Cognitive function was measured utilizing the adapted ACR-Neuropsychological Battery (ACR-NB). CI was defined as a z-score of ≤-1.5 in two or more domains. The serum levels of nine analytes were measured using ELISA. The data were randomly partitioned into a training (70%) and a test (30%) sets. Differences in the analyte levels between patients with and without CI were determined; and their ability to discriminate CI from non-CI was evaluated. Results: Of 290 patients, 40% (n=116) had CI. Serum levels of S100A8/A9 and MMP-9, were significantly higher in patients with CI (p=0.006 and p=0.036, respectively). For most domains of the ACR-NB, patients with CI had higher S100A8/A9 serum levels than those without. Similarly, S100A8/A9 had a negative relationship with multiple CI tests and the highest AUC (0.74, 95%CI: 0.66-0.88) to differentiate between patients with and without CI. Conclusion: In this large cohort of well-characterized SLE patients, serum S100A8/A9 and MMP-9 were elevated in patients with CI. S100A8/A9 had the greatest discriminatory ability in differentiating between patients with and without CI.

Indexed as

Cognitive DysfunctionLupus Erythematosus, SystemicCalgranulin ACalgranulin BHumansMatrix Metalloproteinase 9Calgranulin ACalgranulin BMatrix Metalloproteinase 9MMP9 protein, humanS100A8 protein, humanS100A9 protein, humancognitive impairmentMMP-9 (matrix metalloproteinase 9)neuropsychiatric systemic lupus erythematosus (NPSLE)S100A8/A9systemic lupus erythematosus

Identifiers

PMID38332909
PMCPMC10851148

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.